-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $262

Benzinga·05/08/2026 17:09:04
Listen to the news
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $252 to $262.